Abstract submission information

An abstract is a short statement that gives the reader a comprehensive yet concise understanding of your work.  Your work could be research, a pharmacy practice project, or a case study. 

Your abstract should tell readers what you are going to present and should ignite their interest about your work.  Based on your abstract, if accepted, the reader may decide to attend your presentation, visit your poster, or contact you for more information. 

Your abstract will have two main audiences: 

• Conference delegates: pharmacists, technicians, pharmacy interns, students, conference exhibitors, who will use your abstract to select which sessions to attend or which posters to view 

• Abstract reviewers: will complete a blind review of your abstract to assist the adherence to the submission criteria and assess the quality of your work.  Abstract reviewers use the abstract review criteria in this process. 

Please note individual feedback from abstract reviewers will not be provided to authors. 

• The person responsible for submitting an abstract acknowledges that consent to submit and present has been obtained by all authors of the abstract 
• The author/s agree to allow publication of the abstract content in the Book of Abstracts and conference app 
• Abstract submissions will ONLY be accepted via the online abstract submission portal 
• Abstract submissions that do not conform to all abstract submission criteria will be excluded from consideration. 
• This includes the use of the listed subheadings and any identifying information such as hospitals or workplaces 
• Once an abstract has been submitted you can continue to edit your abstract up until the close of abstract submissions at 11.59pm AEST on Thursday 1 September 2022.  After this, NO changes can be made to abstracts and no further abstracts can be submitted. 
• This includes the listed authors on the abstract 
• Abstracts that contain identifiable information will not be considered for review 
• There can only be one presenting author for each abstract submission/presentation. 
• The presenting author must be an author listed on the original abstract submission.  No changes can be made to listed authors after the close of abstract submissions (11:59pm AEST on Thursday 1 September 2022) 
• You will be asked to enter the presenting author’s contact details, affiliation information, abstract title, presentation (oral or poster), additional or all author(s), at the time of submission. 
• If submitting more than one abstract, each abstract must be submitted under the name of the presenting author. 
• The presenting author is invited to indicate their preference for oral or poster presentation only (or either). However, the final decision is that of the scientific program committee and will be solely determined by the quality and suitability of the abstract. 
• You will be asked to select up to three (3) specialty practice areas that relate to your abstract from the following list:

• All successful presenters (contributed paper oral presenters and poster presenters) must register and pay to attend the full conference (Thursday 1 – Saturday 3 December) by close of early bird, 11:59pm AEDT Thursday 27 October 2022.  Successful presenters who do not register to attend the full conference will have their presentation withdrawn. 
• SHPA student members who have an abstract accepted for MM2022 only need to register for the day of their presentation and not the full conference.

• Abstracts should describe work that has not previously been presented at an SHPA event with a national audience. 
• This includes virtual seminars, virtual branch symposia and entries in the Resident of the Year award
• Publication or presentation of the work at another conference is not a criterion for exclusion. 
• Author details (including institutions, hospital names, or affiliations) MUST NOT appear in the abstract. 
• NOTE: if identifying details are included, the abstract will not be considered for review. 
• Abstracts must be no more than 300 words in length, including mandatory subheadings and references (if included) but excluding the title. 
• The abstract title must be no more than 15 words in length and clearly state the nature of the work. 
• Abstracts must include subheadings applicable to the category under which the abstract is being submitted (see Abstract submission categories below). 
• No tables, graphs, pictures or diagrams are permitted in the abstract. 
• Abbreviations should be avoided where possible.  Any abbreviations used should be spelled out in full on first use. 
• Statistical results should conform with the uniform requirements for manuscripts submitted to biomedical journals. 
• References are not required but may be included.  References should follow the reference citation guide. 
• NOTE: references, if included, will contribute to the total word count. 

Background: briefly describe the rationale for the study. 

Aim/Objective(s): a one sentence statement of the main study objective(s). 

Methods: include study design, methods, intervention. 

Results: a summary of the main results including any relevant statistical analysis. 

Discussion: the main conclusion/interpretation of the results which are supported by the data provided and a clear description of the impact of the work. 

Background: briefly describe the background and rationale for service, program, problem, need, etc. 

Objective(s): describe the concept, service, role, or situation. 

Action (Method): describe the steps taken to identify and resolve a problem(s), implement change, or develop and implement the new program. 

Evaluation: describe the evaluation process of the project and results of evaluation. 

Discussion: describe the concept’s importance and impact on current and/or future practice

Objective: briefly describe the rationale for the case report. 

Clinical Features: relevant demographic information, medical history, presenting problems and diagnoses. 

Literature review: briefly examine current literature relating to or surrounding the case report. 

Pharmacist Interventions, Case Progress and Outcomes: these may be presented together or separately and should detail the pharmacist’s role in the case. 

Discussion: outlining lessons learnt and/or implications/importance of the case report on pharmacy practice.